Preliminary research indicates that combining weight-loss drugs like tirzepatide (Zepbound/Mounjaro) with menopausal hormone therapy (MHT) may significantly increase weight loss in older women. A retrospective study conducted by scientists at the Mayo Clinic and Wayne State University found that women taking both tirzepatide and MHT lost approximately 35% more body weight than those using tirzepatide alone over a 15-month period.
Study Details & Findings
The study analyzed health data from 120 women in their 50s, primarily White, who were either taking tirzepatide alone (80 participants) or in combination with MHT (40 participants). Participants using both medications lost, on average, 19.2% of their initial body weight, compared to the 14% loss observed in the tirzepatide-only group. The 5.2 percentage-point difference was statistically significant, meaning it wasn’t due to random chance. A larger percentage of women in the combined therapy group achieved weight loss exceeding 30%.
Why This Matters
This finding is important because it suggests a potential synergy between GLP-1-based obesity medications and hormone therapy, a combination that could enhance treatment outcomes for postmenopausal women. Weight gain is a common issue during and after menopause, often linked to hormonal shifts and metabolic changes. These findings build on previous research showing similar benefits with semaglutide (another GLP-1 drug) and MHT.
The Science Behind It
Researchers are still investigating why this drug combination appears effective. Initial rodent studies suggest that estrogen may boost the body’s natural GLP-1 signaling, potentially enhancing the weight-loss effects of drugs like tirzepatide. However, other factors could be at play. It’s possible that women undergoing MHT were already more health-conscious, or that symptom relief from hormone therapy improved sleep and lifestyle adherence.
Future Research Needed
The current study is retrospective, meaning it analyzed existing data rather than conducting a controlled experiment. To confirm these findings, scientists plan to conduct randomized controlled trials to definitively establish whether the drug combination truly causes greater weight loss. Future studies will also explore whether this synergy extends to cardiometabolic health benefits, such as improved blood sugar control and reduced heart disease risk.
“Millions of women struggle with weight gain during midlife, and the reality is that we don’t know what the answer is,” says lead researcher Regina Castaneda. “We don’t know why we’re observing these superior weight loss outcomes in women using tirzepatide in addition to hormone therapy.”
The underfunding of menopause research, combined with the relative novelty of GLP-1 drugs, means there are still significant gaps in our understanding. However, these preliminary findings suggest a promising avenue for improving weight management and overall health in postmenopausal women.
